Trial · NCT01408901
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Six-Minute Walk Performance at 12-week Follow-up | A: GM-CSF + Supervised Treadmill Exercise Therapy | 22.2 | 95% Confidence Interval 5.4 to 39.0 | meters | |
| Change in Six-Minute Walk Performance at 12-week Follow-up | B: GM-CSF + Attention Control Group | -6.4 | 95% Confidence Interval -23.0 to 10.1 | meters | |
| Change in Six-Minute Walk Performance at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | 28.5 | 95% Confidence Interval 11.7 to 45.4 | meters | |
| Change in Six-Minute Walk Performance at 12-week Follow-up | D: Placebo + Attention Control Group | -5.0 | 95% Confidence Interval -22.3 to 12.2 | meters | |
| Change in Brachial Artery Flow-mediated Dilation (FMD) at 12-week Follow-up | A: GM-CSF + Supervised Treadmill Exercise Therapy | -0.37 | Inter-Quartile Range -2.50 to 1.28 | percent change | |
| Change in Brachial Artery Flow-mediated Dilation (FMD) at 12-week Follow-up | B: GM-CSF + Attention Control Group | 0.10 | Inter-Quartile Range -1.49 to 1.18 | percent change | |
| Change in Brachial Artery Flow-mediated Dilation (FMD) at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | 0.14 | Inter-Quartile Range -1.53 to 1.50 | percent change | |
| Change in Brachial Artery Flow-mediated Dilation (FMD) at 12-week Follow-up | D: Placebo + Attention Control Group | -0.72 | Inter-Quartile Range -2.02 to 1.64 | percent change | |
| Change in Maximal Treadmill Walking Time at 12-week Follow-up | A: GM-CSF + Supervised Treadmill Exercise Therapy | 3.5 | 95% Confidence Interval 2.5 to 4.5 | minutes | |
| Change in Maximal Treadmill Walking Time at 12-week Follow-up | B: GM-CSF + Attention Control Group | -0.1 | 95% Confidence Interval -1.1 to 0.9 | minutes | |
| Change in Maximal Treadmill Walking Time at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | 4.2 | 95% Confidence Interval 3.2 to 5.2 | minutes | |
| Change in Maximal Treadmill Walking Time at 12-week Follow-up | D: Placebo + Attention Control Group | 0.5 | 95% Confidence Interval -0.6 to 1.6 | minutes | |
| Change in CD34_CD45lo at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | -0.002 | 95% Confidence Interval -0.006 to 0.003 | percentage of cells | |
| Change in CD34_CD45lo at 12-week Follow-up | D: Placebo + Attention Control Group | 0.004 | 95% Confidence Interval -0.001 to 0.008 | percentage of cells | |
| Change in CD34_CD45loCD133_ at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | -0.002 | 95% Confidence Interval -0.005 to 0.002 | percentage of cells | |
| Change in CD34_CD45loCD133_ at 12-week Follow-up | D: Placebo + Attention Control Group | 0.004 | 95% Confidence Interval 0.000 to 0.007 | percentage of cells | |
| Change in CD34_CD45lo_CD31_ at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | -0.003 | 95% Confidence Interval -0.007 to 0.001 | percentage of cells | |
| Change in CD34_CD45lo_CD31_ at 12-week Follow-up | D: Placebo + Attention Control Group | 0.002 | 95% Confidence Interval -0.002 to 0.007 | percentage of cells | |
| Change in CD34_CD45lo_CD31_CD133_ at 12-week Follow-up | C: Placebo + Supervised Exercise Therapy | -0.003 | 95% Confidence Interval -0.006 to 0.001 | percentage of cells | |
| Change in CD34_CD45lo_CD31_CD133_ at 12-week Follow-up | D: Placebo + Attention Control Group | 0.001 | 95% Confidence Interval -0.003 to 0.005 | percentage of cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01408901/results